New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

EyePoint Pharmaceuticals, Inc.

Contributing Author

Recent Articles by EyePoint Pharmaceuticals, Inc.

Sep-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-26	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
Aug-18	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Aug-06	EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference EYPT GlobeNewswire
Aug-06	EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire
Jul-30	EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025 EYPT GlobeNewswire
Jul-29	EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration EYPT GlobeNewswire
Jul-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
Jun-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-28	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-27	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration EYPT GlobeNewswire
May-16	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-13	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-07	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.